Lyell Immunopharma, Inc. financial data

Symbol
LYEL on Nasdaq
Industry
Pharmaceutical Preparations
Location
201 Haskins Way, South San Francisco, CA
State of incorporation
DE
Fiscal year end
December 31
Latest financial report
10-Q - Q3 2024 - Nov 7, 2024

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 1.55K % -13.6%
Debt-to-equity 15.4 % +18.3%
Return On Equity -34.6 % -39%
Return On Assets -30 % -36.1%
Operating Margin -345K % -82534%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 279M shares +10.9%
Common Stock, Shares, Outstanding 257M shares +1.86%
Entity Public Float 654M USD -40.5%
Common Stock, Value, Issued 26K USD +4%
Weighted Average Number of Shares Outstanding, Basic 256M shares +1.99%
Weighted Average Number of Shares Outstanding, Diluted 256M shares +1.99%

Income Statement

Label TTM Value / Value Unit Change %
Revenues 63K USD -99.9%
Research and Development Expense 170M USD -2.33%
General and Administrative Expense 50.7M USD -36.8%
Operating Income (Loss) -217M USD -7.33%
Nonoperating Income (Expense) 13.1M USD +7.73%
Net Income (Loss) Attributable to Parent -204M USD -7.31%
Earnings Per Share, Basic -0.79 USD/shares -3.95%
Earnings Per Share, Diluted -0.79 USD/shares -3.95%

Balance Sheet

Label TTM Value / Value Unit Change %
Cash and Cash Equivalents, at Carrying Value 100M USD -65%
Marketable Securities, Current 340M USD +17.6%
Assets, Current 450M USD -23.3%
Property, Plant and Equipment, Net 88M USD -18.5%
Operating Lease, Right-of-Use Asset 36.7M USD -9.71%
Other Assets, Noncurrent 5.06M USD +14.4%
Assets 619M USD -22.1%
Accounts Payable, Current 3.6M USD -17.6%
Contract with Customer, Liability, Current 0 USD -100%
Liabilities, Current 33.5M USD -4.43%
Contract with Customer, Liability, Noncurrent 0 USD -100%
Operating Lease, Liability, Noncurrent 51.4M USD -12.2%
Other Liabilities, Noncurrent 3.57M USD -5.59%
Liabilities 88.5M USD -9.13%
Accumulated Other Comprehensive Income (Loss), Net of Tax 760K USD
Retained Earnings (Accumulated Deficit) -1.15B USD -21.5%
Stockholders' Equity Attributable to Parent 531M USD -23.9%
Liabilities and Equity 619M USD -22.1%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities -42M USD +9.08%
Net Cash Provided by (Used in) Financing Activities 27K USD
Net Cash Provided by (Used in) Investing Activities 22M USD -31.6%
Common Stock, Shares Authorized 500M shares 0%
Common Stock, Shares, Issued 257M shares +1.86%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect -20M USD -41.5%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents 101M USD -64.9%
Deferred Tax Assets, Valuation Allowance 248M USD +37.9%
Deferred Tax Assets, Gross 263M USD +33.8%
Operating Lease, Liability 58.6M USD -9.38%
Payments to Acquire Property, Plant, and Equipment 1.53M USD -84.2%
Comprehensive Income (Loss), Net of Tax, Attributable to Parent -202M USD -11.5%
Lessee, Operating Lease, Liability, to be Paid 75.1M USD -13%
Property, Plant and Equipment, Gross 154M USD -0.71%
Operating Lease, Liability, Current 7.13M USD +17.7%
Lessee, Operating Lease, Liability, to be Paid, Year Two 12.2M USD +2.95%
Lessee, Operating Lease, Liability, to be Paid, Year One 11.9M USD +4.51%
Operating Lease, Weighted Average Discount Rate, Percent 0.09 pure 0%
Lessee, Operating Lease, Liability, Undiscounted Excess Amount 16.5M USD -24%
Lessee, Operating Lease, Liability, to be Paid, Year Three 12.6M USD +2.95%
Deferred Tax Assets, Operating Loss Carryforwards 133M USD +25%
Preferred Stock, Shares Issued 0 shares
Preferred Stock, Shares Authorized 10M shares 0%
Unrecognized Tax Benefits 400K USD 0%
Lessee, Operating Lease, Liability, to be Paid, Year Four 12.9M USD +2.95%
Additional Paid in Capital 1.68B USD +2.13%
Preferred Stock, Shares Outstanding 0 shares
Depreciation, Depletion and Amortization 5.02M USD -0.06%
Deferred Tax Assets, Net of Valuation Allowance 14.9M USD -10.2%
Share-based Payment Arrangement, Expense 33.5M USD -41.2%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%